Neuroplasticity and cellular resilience in mood disorders

Molecular Psychiatry

Volumn 5, Issue 6, 2000, Pages 578-593

  Manji, H K ^a,b   Moore, G J ^a   Rajkowska, G ^c   Chen, G ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Atrophy; bcl 2; Cell death; Gray matter; Lithium; MAP kinase; N acetylaspartate; Neurite; Neurogenesis; Neuroprotection; Neurotrophic

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; LITHIUM; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; VALPROIC ACID;

AFFECTIVE NEUROSIS; ARTICLE; CELL COUNT; CELL SURVIVAL; DISEASE COURSE; GLIA CELL; HUMAN; NERVE CELL; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033659957     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000811     Document Type: Article

References (163)

1. The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment
2. The role of inflammatory mediators in the biology of major depression: Central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection
3. Association between depression and mortality in older adults: The Cardiovascular Health Study
4. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
5. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study
6. Neuroplasticity failure in Alzheimer's disease: Bridging the gap between plaques and tangles
7. From metapsychology to molecular biology: Explorations into the nature of anxiety
8. A molecular and cellular theory of depression
9. Clinical and preclinical evidence for the neurotrophic and effects of mood-stabilizing agents: Implications for the pathophysiology and treatment of manic-depressive illness
10. Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders. Comparisons with controls or patients with schizophrenia
11. The anatomy of mood disorders: Review of structural neuroimaging studies
12. Subgenual prefrontal cortex abnormalities in mood disorders
13. Neuroimaging studies of mood disorders
14. Hippocampal atrophy in recurrent major depression
15. Depression duration but not age predicts hippocampal volume loss in medical healthy women with recurrent major depression
16. Structural neuroimaging and mood disorders: Recent findings, implications for classification, and future directions
17. Subgenual cingulate cortex volume in first-episode psychosis
18. Hippocampal volume reduction in major depression
19. Hippocampal abnormalities in depression
20. Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression
21. Hippocampal remodeling and damage by corticosteroids: Implications for mood disorders
22. The possibility of neurotoxicity in the hippocampus in major depression: A primer on neuron death
23. Stress and hippocampal plasticity
24. Functions of N-acetyl-L-aspartate and N-acetyl-L-aspartylglutamate in the vertebrate brain: Role in glial cell-specific signaling
25. N-acetylaspartate in neuropsychiatric disorders
26. Inhibition of N-acetylaspartate production: Implications for 1H MRS studies in vivo
27. Neuronal pathology in the hippocampal area of patients with bipolar disorder: A H-1-MRSI study
28. A 1H-MRSI hippocampal study in bipolar patients with a history of alcohol abuse
29. Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorders
30. Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy
31. Phosphorous-31 magnetic resonance spectroscopy and ventricular enlargement in bipolar disorder
32. Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy
33. 31P-MRS
34. Abnormal frontal lobe phosphorus metabolism in bipolar disorder
35. Decreased temporal lobe phosphomonoesters in bipolar disorder
36. 31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients
37. 31P-MRS
38. In vivo 31P-MRS of the frontal lobe in neurolepticnaive first-episode psychosis: Preliminary observations
39. 7Li magnetic resonance spectroscopy
40. Altered brain energy metabolism in lithium-resistant bipolar disorder detected by photic stimulated 31P-MR spectroscopy
41. Reduced volume of limbic system-affiliated basalganglia in mood disorders: Preliminary data from a postmortem study
42. Post-mortem studies on bipolar disorder
43. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression
44. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder
45. Significant reduction of calretinin-IR neurons in layer II in the anterior cingulate cortex in subjects with affective disorders
46. A comparison of the density of pyramidal and nonpyramidal neurons in the anterior cingulate cortex of schizophrenics and manic depressives
47. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives
48. Histopathology of the prefrontal cortex in depression: What does it tell us about dysfunctional monoaminergic circuits
49. Signal transduction pathways: Molecular targets for lithium's action
50. Signaling: Cellular insights into the pathophysiology of bipolar disorder
51. Marked glial neuropathology in prefrontal cortex distinguishes bipolar disorder from schizophrenia
52. Postmortem studies in blood disorders indicate altered numbers of neurons and glial cells
53. GFAP immunoreactivity in the dorsolateral prefrontal cortex separates young from old adults with major depressive disorder
54. Glial reduction in the subgenual prefrontal cortex in mood disorders
55. Mind glue: Implications of glial cell biology for psychiatry
56. Neural circuits in the 21st century: Synaptic networks of neurons and glia
57. Stress, glucocorticoids, and damage to the nervous system: The current state of confusion
58. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease
59. Cerebral atrophy in Cushing's disease
60. Developmental traumatology. Part II: Brain development
61. Mechanism of glutamate release from rat hippocampal slices during in vitro ischemia
62. Acute inhibition but chronic upregulation and stabilization of glutamate uptake in synaptosomes by lithium
63. Calcium signaling in the ER: Its role in neuronal plasticity and neurodegenerative disorders
64. The calcium second messenger system in bipolar disorders: Data supporting new research directions
65. High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder
66. Signal transduction abnormalities in bipolar disorder
67. ATP2A2 mutations in Darier's disease and their relationship to neuropsychiatric phenotypes
68. Elevated basal and thapsigargin stimulated intracellular calcium of platelets and lymphocytes from bipolar affective disorder patients measured by a fluorometric microassay
69. The mood stabilizing agents lithium and valproate robustly increase the expression of the neuroprotective protein bcl-2 in the CNS
70. Long term lithium treatment suppresses p53 and Bax expression but increases bcl-2 expression
71. Lithium at 50: Have the neuroprotecrive effects of this unique cation been overlooked?
72. Regulation of signal transduction pathways by mood stabilizing agents: Implications for the pathophysiology and treatment of bipolar affective disorder
73. Lithium uprgulates the cytoprotective protein bcl-2 in vitro and in the CNS in vivo: A role for neurotrophic and neuroprotective effects in manic-depressive illness
74. Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78
75. Stress alters the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus
76. Repeated stress increases catalytic TrkB mRNA in rat hippocampus
77. Neurotrophins and neuronal plasticity
78. BDNF promotes the survival and sprouting of serotonergic axons in the rat brain
79. Evidence that increased hippocampal expression of the cytokine interleukin-1β is a common trigger for age- and stress-induced impairments in long-term potentiation
80. Apoptosis in neural development and disease
81. The Bcl-2 protein family: Arbiters of cell survival
82. Bcl-2 gene family in the nervous system
83. The Bcl-2 gene family and apoptosis
84. Mitochondrial control of cell death
85. Reduced loading of intracellular Ca(2+) stores and downregulation of capacitative Ca(2+) influx in Bcl-2-overexpressing cells
86. Apoptotic crosstalk between the endoplasmic reticulum and mitochondria controlled by Bcl-2
87. Modulation of endoplasmic reticulum calcium pump by Bcl-2
88. Maintenance of calcium homeostasis in the endoplasmic reticulum by Bcl-2
89. Bcl-2 promotes regeneration of severed axons in mammalian CNS
90. Bcl-2 influences axonal growth rate in embryonic sensory neurons
91. BCL2 regulates neural differentiation
92. Bcl-2 accelerates the neuronal differentiation: New evidence approaching to the biofunction of bcl-2 in the neuronal system
93. Neuronal cell death
94. Intracellular signaling pathways activated by neurotrophic factors
95. 2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism
96. Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons
97. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms
98. Neurogenesis in the adult human hippocampus
99. Neurogenesis in the neocortex of adult primates
100. Stress and hippocampal neurogenesis
101. Restoring production of hippocampal neurons in old age
102. Neuronal plasticity and survival in mood disorders
103. Induction of CRE gene expression by antidepressant treatment
104. Identification of a signaling pathway involved in calcium regulation of BDNF expression
105. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments
106. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus
107. Antidepressant treatment increases the birth and survival of hippocampal neurons
108. Antidepressants induce regeneration of catecholaminergic axon terminals in the rate cerebral cortex
109. Tianeptine attenuates stress-induced morphological changes in the hippocampus
110. Repeated ECS and fluoxetine administration have equivalent effects on hippocampal synaptic plasticity
111. Enhancement of hippocampal neurogenesis by lithium
112. Lithium attenuates p53 levels in human neuroblastoma SH-SH-SY5Y cells
113. A molecular mechanism for the effect of lithium on development
114. Signal transduction by the Wnt family of ligands
115. Beta-catenin: A key mediator of Wnt signaling
116. Anti-bipolar therapy: Mechanism of action of lithium
117. Destabilization of beta catenin by mutations in presenilin-1 potentiates neuronal apoptosis
118. Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex
119. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3 Kinase/Akt cell survival pathway
120. Glycogen synthase kinase-3 facilitates staurosporine- and heat shock-induced apoptosis: Protection by lithium
121. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons
122. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3
123. Lithium reduces tan phosphorylation: Effects in living cells and in neurons at therapeutic concentrations
124. Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal
125. The mood stabilizing agent valproate inhibits the activity of glycogen synthase kinase 3
126. Lithium promotes short-term survival of PC12 cells after serum and NGF deprivation
127. Lithium induces apoptosis in immature cerebellar granule cells but promotes survival of mature neurons
128. Lithium protects against ouabain-induced cell death
129. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration
130. Lithium delays the radiation-induced apoptotic process in external granule cells of mouse cerebellum
131. A protective effect of lithium on rat behaviour altered by ibotenic acid lesions of the basal forebrain cholinergic system
132. + protection of cerebellar granule neurons switched to non depolarizing medium
133. Chronic lithium treatment robustly protects neurons in the central nervous System against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx
134. Lithium protects rat cerebellar granule cells against apoptosis induced by anticonvulsants, phenytoin and carbamazepine
135. Synergistic effects of tetrahydroaminoacridine and lithium on cholinergic function after excitotoxic basal forebrain lesions in rat
136. Effects of chronic lithium treatment on ornithine decarboxylase induction and excitotoxic neuropathology in the rat
137. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats
138. Lithium inhibits striatal damage in an animal model of Huntington disease
139. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons
140. Experience-dependant regulation of adult hippocampal neurogenesis: Effects of long-term stimulation and stimulus withdrawal
141. Antidegenerative effects of Mg(2+) valproate in cultured cerebellar neurons
142. 2+ deregulation, and cytoskeletal pathology
143. +
144. Valproate robustly enhances AP-1 mediated gene expression
145. The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades
146. CREB couples neurotrophin signals to survival messages
147. Valproic acid activates mitogen activated protein kinases and promotes neurite growth
148. Lithium increases N-acetyl-aspartate in the human brain: In vivo evidence in support of bcl-2's neurotrophic effects?
149. Pharmacologic in human grey matter
150. N-acetyl-L-aspartic acid: A literature review of a compound prominent in 1H-NMR spectroscopic studies of brain
151. Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder
152. Twelve-month outcome after a first hospitalization for affective psychosis
153. 12-Month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode
154. Structural brain abnormalities in first-episode mania
155. Magnetic resonance assessment of cerebral perfusion in depressed cardiac patients: Preliminary findings
156. Cerebrovascular disease and depression symptoms in the cardiovascular health study
157. A quantitative magnetic resonance imaging study of caudate and lenticular nucleus gray matter volume in primary unipolar major depression: Relationship to treatment response and clinical severity
158. Hippocampal volume in primary unipolar major depression: A magnetic resonance imaging study
159. Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins
160. Designing small-molecule switches for protein - Protein interactions
161. Adult brain neurogenesis and psychiatry: A novel theory of depression